The global myelodysplastic syndrome (MDS) treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are driving the market growth include a rise in public awareness about myelodysplastic syndromes and their early diagnosis and the availability of new treatment options for MDS. Moreover, early diagnosis of MDS is important, as it significantly increases the quality of life in patients, reducing the chances of recurrent blood transfusion. Increasing regulatory approvals is another factor that is anticipated to fuel the market during the forecast period. For instance, in November 2018, Lupin obtained the US FDA approval of its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.’s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which incorporates previously treated and untreated, de novo, as well as secondary MDS of all French-American-British subtypes.
To Request a Sample of our Report on Global Myelodysplastic Syndrome (MDS) Treatment Market: https://www.omrglobal.com/request-sample/myelodysplastic-syndrome-mds-treatment-market
Several Drug manufacturing companies and government organizations are focusing more on spreading awareness about the disease by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceutical company conducted a campaign for Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease throughout the month. Moreover, increasing launch and approval of Azacitidine in some regions is expected to drive the market growth during the forecast period. For instance, in February 2018, BeiGene, Ltd. introduced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is accredited in China for patients with intermediate-2/excessive-chance myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukaemia. It is marketed in China by BeiGene under an exclusive license from Celgene Corp.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Celgene Corp., Otsuka Pharmaceutical Co., Ltd., and Dr. Reddy’s Laboratories Ltd., among others.
A full Report of Global Myelodysplastic Syndrome (MDS) Treatment Market is Available @ https://www.omrglobal.com/industry-reports/myelodysplastic-syndrome-mds-treatment-market
Global Myelodysplastic Syndrome (MDS) Treatment Market Report by Segment
By Drug
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
Global Myelodysplastic Syndrome (MDS) Treatment Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/myelodysplastic-syndrome-mds-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
